MIV Therapeutics

MIV Therapeutics was a Vancouver-based biomedical company that developed biocompatible coatings for medical devices, specifically targeting the cardiovascular market. The company's core innovation was a proprietary Hydroxyapatite (HA) coating technology designed to replace traditional polymer coatings on drug-eluting stents, which were often linked to inflammatory responses and late-stage thrombosis. Their product portfolio included the GenX hydroxyapatite-coated stent and the VESTAsync sirolimus-eluting stent. Although the company achieved CE Mark approval for its GenX stent and conducted several clinical trials, it ultimately ceased operations due to financial insolvency. MIV Therapeutics was previously traded on the OTC Bulletin Board under the symbol MIVT.